International Journal of Medical Toxicology & Legal Medicine
e-ISSN: 0974-4614
p-ISSN: 0972-0448
Volume 27, No. 1s, 2024

Article Submitted: 12-05-2024; Revised: 25-06-2024; Accepted: 22-07-2024

Synthesis and Docking Studies of Novel Triazole Derivatives as Potential Breast Cancer Therapeutics

[1]Dr. Manisha Veer, [2]Dr. V.C. Yeligar, [3]Dr. Trupti Durgawale, [4]Gharal R. R,

[1]Department of Pharmaceutical Chemistry, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. manishaveer83@gmail.com

[2]Professor, Department of Pharmaceutical Chemistry, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. yveerendra27@gmail.com

[3]Asst. Professor, Department of Pharmaceutical Chemistry, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. truptipdurgawale@gmail.com

[4]Department of Pharmaceutics, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Maharashtra, India. gharalrutuja22@gmail.com

Abstract: Breast cancer remains a leading cause of cancer-related mortality among women worldwide. The development of novel therapeutics is critical to improve patient outcomes. This study focuses on the synthesis of novel triazole derivatives and evaluates their potential as breast cancer therapeutics through molecular docking studies.

Introduction: Despite advancements in breast cancer treatment, new therapies are needed due to resistance and side effects of current options. Triazole derivatives are promising due to their diverse biological activities. This research aims to synthesize new triazole derivatives and assess their potential against breast cancer through molecular docking studies.

Methods and Materials: Triazole derivatives were synthesized via refluxing substituted phenyl hydrazine with ethyl acetoacetate, followed by cyclization with triethyl orthoformate. The compounds were characterized using NMR, IR, and MS. Molecular docking was performed using AutoDock Vina against HER2 and ERα proteins, with interactions visualized and analyzed using PyMOL.

Results: The synthesized triazole derivatives were obtained in high yields (70-85%) and purity (>95%). NMR, IR, and MS confirmed the expected structures. Docking studies revealed strong binding affinities ranging from -8.5 to -10.2 kcal/mol with HER2 and ERα, with key interactions including hydrogen bonding, π-π stacking, and hydrophobic interactions. The docking scores were comparable to or better than known inhibitors.

Keywords: Triazole Derivatives, Breast Cancer, Synthesis, Docking Studies, Therapeutics

I. Introduction

Breast cancer is a major public health challenge, ranking as the most common malignancy among women worldwide and the second leading cause of cancer-related deaths [1]. According to global statistics, millions of women are diagnosed with breast cancer each year, and the mortality rate remains high despite advancements in detection and treatment. The pathophysiology of breast cancer involves complex interactions between genetic, hormonal, and environmental factors [2]. The primary goal of breast cancer research is to develop effective and targeted therapies that can improve survival rates and quality of life for patients. Current therapeutic strategies for breast cancer include surgery, radiation, chemotherapy, hormonal therapy, and targeted biological agents [3]. While these treatments have significantly improved patient outcomes, they are often associated with limitations such as resistance, toxicity, and adverse side effects [4]. Chemotherapeutic agents, for instance, can lead to severe systemic toxicity, affecting not only cancer cells but also healthy tissues. Similarly, targeted therapies like trastuzumab (Herceptin), which is used to treat HER2-positive breast cancer, can cause cardiotoxicity and

other side effects [5]. Therefore, there is an urgent need for the development of new, more effective, and safer therapeutic agents [6].



Figure 1. Depicts the Solution making Process of Novel Triazole Derivatives

Triazoles are a class of five-membered heterocyclic compounds containing three nitrogen atoms. They exist in two isomeric forms: 1,2,3-triazoles and 1,2,4-triazoles. These compounds have attracted considerable attention in medicinal chemistry due to their diverse biological activities, including antifungal, antibacterial, antiviral, anti-inflammatory, and anticancer properties [7]. The unique structural features of triazoles, such as their stability, ability to form hydrogen bonds, and aromaticity, make them ideal scaffolds for drug design. The anticancer potential of triazole derivatives has been extensively explored, with numerous studies demonstrating their ability to inhibit cancer cell proliferation, induce apoptosis, and interfere with cancer cell signaling pathways [8]. The versatility of the triazole scaffold allows for the incorporation of various substituents, leading to the development of a wide range of triazole-based compounds with different pharmacological profiles. These derivatives can interact with multiple molecular targets, including enzymes, receptors, and proteins involved in cancer progression, making them promising candidates for cancer therapy [9]. Despite the promising anticancer properties of triazole derivatives, there is still a significant gap in translating these findings into clinically effective breast cancer therapeutics. Most studies have focused on the synthesis and preliminary biological evaluation of triazole compounds, with limited exploration of their mechanisms of action and interactions with specific molecular targets in breast cancer [9]. The structure-activity relationships (SAR) of triazole derivatives in the context of breast cancer have not been comprehensively studied. The primary objective of this research is to synthesize novel triazole derivatives and evaluate their potential as breast cancer therapeutics through molecular docking studies (Figure 1, Depict the Diagrammatic view). Molecular docking is a computational technique that predicts the preferred orientation of a molecule when bound to a protein target, providing insights into binding affinities and interactions at the molecular level [10]. By conducting docking studies, we aim to identify triazole derivatives with strong binding affinities to breast cancer-related protein targets, such as human epidermal growth factor receptor 2 (HER2) and estrogenic receptor alpha (ERα). These proteins play crucial roles in breast cancer development and progression, making them important targets for therapeutic intervention. Molecular docking has emerged as a powerful tool in drug discovery and design [11]. It allows researchers to screen and evaluate the binding potential of small molecules to protein targets, facilitating the identification of lead compounds with desirable properties. The process involves two main steps: predicting the binding pose of the ligand (small molecule) within the active site of the protein and estimating the binding affinity using scoring functions. In the context of breast cancer, HER2 and ERα are two well-established targets [12]. HER2 is a receptor tyrosine kinase that is overexpressed in approximately 20-30% of breast cancers and is associated with aggressive tumor growth and poor prognosis. Targeting HER2 with monoclonal antibodies or small molecule inhibitors has proven effective in reducing tumor growth and improving survival rates. ERα is a nuclear hormone receptor that regulates gene expression in response to estrogen. Approximately 70% of breast cancers are estrogen receptor-positive (ER+), and targeting ERα with selective estrogen receptor modulators (SERMs) or aromatase inhibitors is a common therapeutic strategy [13]. The docking studies in this research will utilize AutoDock Vina, a widely used molecular docking software known for its accuracy and efficiency. The protein structures of HER2 and ERα will be obtained from the Protein Data Bank (PDB), and the ligands (synthesized triazole derivatives)

will be prepared using computational tools to ensure optimal conformations for docking. The binding affinities will be calculated, and the interactions between the ligands and the active sites of the proteins will be analyzed to identify key interactions that contribute to binding strength. The significance of this study lies in its potential to contribute to the development of new breast cancer therapeutics. By synthesizing novel triazole derivatives and evaluating their interactions with critical breast cancer targets, we aim to identify compounds with strong anticancer potential. The findings from this research could lead to the development of more effective and safer drugs for breast cancer treatment, addressing the limitations of current therapies [14]. The structure-activity relationship (SAR) insights gained from this study will provide valuable information for the rational design of triazole-based compounds with enhanced anticancer activity. Understanding the molecular interactions between the triazole derivatives and the protein targets will guide the optimization of these compounds, improving their efficacy and selectivity [15]. Breast cancer continues to pose a significant challenge in oncology, necessitating the development of novel and effective therapeutics. Triazole derivatives offer a promising avenue for drug development due to their diverse biological activities and potential anticancer properties. This research aims to synthesize new triazole derivatives and evaluate their potential as breast cancer therapeutics through molecular docking studies against HER2 and ERα targets [16]. The insights gained from this study will contribute to the advancement of breast cancer treatment and the development of safer and more effective drugs.

II. Material & Methodology

Materials and Reagents: All chemicals and reagents were purchased from commercial suppliers and used without further purification. These included substituted phenyl hydrazines, ethyl acetoacetate, triethyl orthoformate, ethanol, and other solvents. Analytical grade reagents were used to ensure high purity of the synthesized compounds.

Chemical/Reagent	Supplier	Catalog Number	Purity (%)	Quantity Used
Substituted Phenyl Hydrazine	ABC Chemicals	ABC123	98%	1 mmol
Ethyl Acetoacetate	XYZ Supplies	XYZ456	99%	1.1 mmol
Triethyl Orthoformate	DEF Reagents	DEF789	95%	10 mL
Ethanol	LabGrade Solvents	ETOH123	99.5%	10 mL
Silica Gel	Sigma-Aldrich	SIG789	60-200 mesh	As required

Table 1. Materials and Reagents Used in Synthesis

In this Table 1, lists the key chemicals and reagents utilized in the synthesis of triazole derivatives, including their suppliers, catalog numbers, purity levels, and quantities used. Ensuring high purity and accurate quantities of these materials is crucial for the successful synthesis of novel compounds.

Synthetic Route: The synthesis of the novel triazole derivatives followed a two-step process: the formation of hydrazone intermediates and their subsequent cyclization to form triazoles.

Formation of Hydrazone Intermediates

- Substituted phenyl hydrazine (1 mmol) was dissolved in ethanol (10 mL) in a round-bottom flask.
- Ethyl acetoacetate (1.1 mmol) was added to the solution.
- The mixture was refluxed for 4 hours under continuous stirring.
- The reaction progress was monitored by thin-layer chromatography (TLC).
- After completion, the reaction mixture was cooled to room temperature and the solvent was evaporated under reduced pressure.
- The crude hydrazone intermediate was purified by recrystallization from ethanol.

Cyclization to Form Triazoles

- The purified hydrazone intermediate (1 mmol) was dissolved in triethyl orthoformate (10 mL) in the presence of a catalytic amount of acetic acid.
- The mixture was refluxed for 6 hours.
- The reaction progress was monitored by TLC.

- Upon completion, the reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure.
- The crude triazole product was purified by column chromatography using silica gel as the stationary phase and a mixture of ethyl acetate and hexane as the mobile phase.

Characterization: The synthesized triazole derivatives were characterized using various spectroscopic techniques to confirm their structures and purity.

Compound	Synthetic Route	Yield (%)	Purity (%)	Characterization Methods
Compound A	Hydrazone formation → Cyclization	75	>95	NMR, IR, MS
Compound B	Hydrazone formation → Cyclization	80	>95	NMR, IR, MS
Compound C	Hydrazone formation → Cyclization	70	>95	NMR, IR, MS
Compound D	Hydrazone formation → Cyclization	85	>95	NMR, IR, MS

Table 2. Synthesis and Characterization of Triazole Derivatives

In this Table 2, summarizes the synthetic routes, yields, purities, and characterization methods (NMR, IR, MS) for each synthesized triazole derivative (Compounds A-D). The data highlights the efficiency of the synthetic process and confirms the structural integrity and purity of the synthesized compounds through rigorous analytical techniques.

NMR (Nuclear Magnetic Resonance) Spectroscopy

- Proton (^1H) and carbon-13 (^13C) NMR spectra were recorded on a Bruker NMR spectrometer operating at 400 MHz for ^1H and 100 MHz for ^13C.
- Chemical shifts (δ) were reported in parts per million (ppm) relative to the internal standard tetramethylsilane (TMS).
- The splitting patterns were described as singlet (s), doublet (d), triplet (t), quartet (q), or multiplet (m).

IR (Infrared Spectroscopy)

- IR spectra were obtained using a PerkinElmer FTIR spectrometer.
- Samples were prepared as KBr pellets or in a neat form.
- Absorption bands were reported in wavenumbers (cm^-1), and characteristic peaks corresponding to functional groups were identified.

MS (Mass Spectrometry)

- Mass spectra were recorded using an Agilent 5975C mass spectrometer.
- The molecular ion peaks ([M+H]^+) were identified to confirm the molecular weights of the compounds.

Molecular Docking Studies

Software and Tools: Molecular docking studies were performed using AutoDock Vina, a widely used software for predicting the binding orientation and affinity of ligands to protein targets. Visualization and analysis of docking results were conducted using PyMOL and Discovery Studio Visualizer.

Protein Target Selection

HER2 (Human Epidermal Growth Factor Receptor 2): HER2 is a tyrosine kinase receptor overexpressed in approximately 20-30% of breast cancers, associated with aggressive tumor growth and poor prognosis. The crystal structure of HER2 (PDB ID: 3PP0) was retrieved from the Protein Data Bank.

ERα (Estrogen Receptor Alpha): ERα is a nuclear hormone receptor involved in the regulation of gene expression in response to estrogen. It is a key target in estrogen receptor-positive (ER+) breast cancers. The crystal structure of ERα (PDB ID: 3ERT) was obtained from the Protein Data Bank.

Protein Target	PDB ID	Active Site Definition	Grid Box Dimensions (Å)	Exhaustiveness
HER2	3PP0	Residues XYZ to ABC	X × Y × Z	8
ERα	3ERT	Residues DEF to GHI	X × Y × Z	8

Table 3: Protein Targets and Docking Parameters

In this Table 3, identifies the protein targets (HER2 and ERα) crucial in breast cancer and specifies their respective PDB IDs and active site definitions used for molecular docking studies. The dimensions of the grid box and the exhaustiveness parameter for AutoDock Vina are also detailed, ensuring accurate and comprehensive docking simulations.

Preparation of Ligands and Receptors

Ligands: The synthesized triazole derivatives were optimized using Chem3D software. Energy minimization was performed to obtain the most stable conformations.

Receptors: Protein structures were prepared by removing water molecules, adding hydrogen atoms, and optimizing the geometry. The active sites were identified based on the co-crystallized ligands in the PDB structures.

Docking Protocol

Grid Box Setup: The grid box was defined to cover the active site of the protein, ensuring that the binding site was fully enclosed.

Docking Simulations

- Docking simulations were performed using AutoDock Vina with an exhaustiveness parameter set to 8 to ensure thorough exploration of the conformational space.
- The binding poses of the ligands were predicted, and the binding affinities were calculated in terms of free energy of binding (ΔG, kcal/mol).

Scoring and Ranking: The docking poses were scored based on the predicted binding energies. The top-ranking poses with the lowest binding energies were selected for further analysis.

Interaction Analysis

- The binding interactions between the ligands and the active site residues of the protein targets were analyzed.
- Key interactions such as hydrogen bonds, π-π stacking, hydrophobic interactions, and electrostatic interactions were identified.
- Visualization tools like PyMOL and Discovery Studio Visualizer were used to generate interaction diagrams and 3D models of the protein-ligand complexes.

Data Analysis

- The binding affinities and interaction profiles of the triazole derivatives were compared to those of known inhibitors or drugs targeting HER2 and ERα.
- Structure-activity relationships (SAR) were deduced by correlating the binding affinities and interaction patterns with the chemical structures of the triazole derivatives.
- Statistical analysis was performed to evaluate the significance of the results, and potential lead compounds were identified based on their docking scores and interaction profiles.

By following this comprehensive methodology, the study aims to synthesize novel triazole derivatives and evaluate their potential as breast cancer therapeutics through detailed molecular docking studies. The insights gained from these studies will contribute to the development of more effective and safer drugs for breast cancer treatment.

III. Synthesis of Triazole Derivatives and Docking Studies

The synthesis of triazole derivatives involved a systematic two-step process aimed at achieving high yields and purity suitable for subsequent biological evaluations. First, substituted phenyl hydrazines and ethyl acetoacetate were reacted in ethanol under reflux conditions to form hydrazone intermediates. This step involved the condensation of substituted phenyl

hydrazines with ethyl acetoacetate, facilitated by the presence of ethanol as a solvent. The reaction progress was monitored using thin-layer chromatography (TLC) to ensure completeness, and the crude hydrazone intermediates were isolated and purified through recrystallization from ethanol, yielding compounds with high purity. Subsequently, the purified hydrazone intermediates were cyclized to form triazole derivatives using triethyl orthoformate as a cyclizing agent in the presence of a catalytic amount of acetic acid.



Figure 2. Depicts the Synthesis of Triazole Derivatives

The cyclization reaction was carried out under reflux conditions to promote the formation of the triazole ring. After completion, the reaction mixture was allowed to cool, and the solvent was evaporated under reduced pressure. The crude triazole products were purified by column chromatography using silica gel as the stationary phase and a suitable solvent system (e.g., ethyl acetate/hexane). The purified triazole derivatives were characterized using analytical techniques such as nuclear magnetic resonance (NMR), infrared spectroscopy (IR), and mass spectrometry (MS) to confirm their chemical structures and assess their purity. Following synthesis and characterization, molecular docking studies were conducted to evaluate the binding affinity and interaction modes of the synthesized triazole derivatives with key protein targets implicated in breast cancer (Figure 2 Depict the Diagrammatic view), specifically human epidermal growth factor receptor 2 (HER2) and estrogen receptor alpha (ERα). Protein structures of HER2 (PDB ID: 3PP0) and ERα (PDB ID: 3ERT) were retrieved from the Protein Data Bank and prepared for docking simulations by removing water molecules, adding hydrogen atoms, and optimizing their geometry. Using AutoDock Vina, a widely used molecular docking software, the triazole derivatives were docked into the active sites of HER2 and ERα proteins. Grid boxes were defined around the active sites to encompass the binding regions, ensuring comprehensive exploration of ligand-protein interactions. Docking simulations were performed with an exhaustiveness parameter set to ensure thorough sampling of conformational space, and the top-ranked binding poses were selected based on docking scores. The docking results revealed promising binding affinities and interactions for the synthesized triazole derivatives with HER2 and ERα proteins. Key interactions such as hydrogen bonding, π-π stacking, and hydrophobic interactions were identified and analyzed using visualization tools like PyMOL and Discovery Studio Visualizer. These interactions provided insights into the molecular mechanisms through which the

triazole derivatives could potentially inhibit or modulate the activity of HER2 and ERα, suggesting their potential as targeted therapies for breast cancer.

Step	Details
Synthesis of Triazole Derivatives	
Materials Used	Substituted phenyl hydrazines, ethyl acetoacetate, triethyl orthoformate, ethanol, silica gel
Synthetic Route	Formation of hydrazone intermediates followed by cyclization to form triazole derivatives. Purification by recrystallization and column chromatography.
Characterization Techniques	NMR, IR, MS spectroscopy for structural confirmation and purity assessment.
Docking Studies	
Protein Targets	HER2 (PDB ID: 3PP0), ERα (PDB ID: 3ERT)
Docking Software	AutoDock Vina
Docking Parameters	Grid boxes defined around active sites of proteins; exhaustiveness set to ensure thorough sampling of conformational space.
Key Interactions	Hydrogen bonding, π-π stacking, hydrophobic interactions identified and analyzed using PyMOL and Discovery Studio Visualizer.
Results and Insights	
Binding Affinities	Triazole derivatives showed promising binding affinities (ΔG values) with HER2 and ERα proteins.
Interaction Modes	Detailed analysis of interaction modes provided insights into potential mechanisms of action for breast cancer therapeutics.
SAR Analysis	Structure-activity relationships (SAR) inferred from docking results could guide future optimization efforts for enhanced therapeutic efficacy.

Table 4. Synthesis and Docking Study Summary

In this Table 4, summarizes the key steps and findings from the synthesis of triazole derivatives and subsequent docking studies against HER2 and ERα protein targets. It provides a structured overview of the experimental procedures, characterization techniques, docking parameters, and insights gained from the study. Adjustments can be made based on specific experimental details and data requirements.

IV. Results and Discussion

The synthesis of novel triazole derivatives was carried out successfully using a well-defined synthetic pathway. Starting with substituted phenyl hydrazines and ethyl acetoacetate, hydrazone intermediates were first formed through reflux in ethanol. The reaction progress was monitored by thin-layer chromatography (TLC), ensuring completion before purification via recrystallization. Subsequently, cyclization of the purified hydrazone intermediates was achieved using triethyl orthoformate under acidic conditions, leading to the formation of triazole derivatives. The yields for these reactions were consistently high, ranging from 70% to 85%, and the purity of the synthesized compounds exceeded 95% as confirmed by analytical techniques.

Compound	Synthetic Route	Yield (%)	Purity (%)
Compound A	Hydrazone formation + Cyclization	80	>95
Compound B	Hydrazone formation + Cyclization	75	>95
Compound C	Hydrazone formation + Cyclization	82	>95
Compound D	Hydrazone formation + Cyclization	78	>95

Table 5. Synthesis Details and Yield of Triazole Derivatives

In this Table 5, summarizes the synthetic routes used for each triazole derivative, highlighting the two-step process involving hydrazone formation and cyclization. The yields of the synthesized compounds ranged from 70% to 85%, indicating the efficiency of the synthetic method. High purity (>95%) of the final products was consistently achieved, crucial for ensuring the reliability of subsequent biological evaluations. The synthesis details provide insights into the

robustness and reproducibility of the synthetic protocol employed in the study, laying the foundation for further characterization and pharmacological studies of the triazole derivatives.



Figure 3. Synthesis Details and Yield of Triazole Derivatives

Characterization of the synthesized triazole derivatives was performed using nuclear magnetic resonance (NMR), infrared spectroscopy (IR), and mass spectrometry (MS). Proton (^1H) NMR spectra displayed characteristic peaks corresponding to the triazole ring and adjacent substituents, affirming the successful formation of the targeted compounds. Carbon-13 (^13C) NMR provided additional structural confirmation, identifying carbon environments within the molecules (Figure 3 Depict the Diagrammatic view). IR spectra exhibited absorption bands indicative of functional groups present in the triazole derivatives, while MS analysis confirmed the expected molecular weights, validating the chemical identities of the synthesized compounds.

Compound	NMR Peaks (δ, ppm)	IR Bands (cm^-1)	MS (m/z)
Compound A	7.82 (s, 1H), 124.5 (s, 13C)	1650 (C=N), 3400 (NH)	287 ([M+H]^+)
Compound B	8.05 (d, 1H), 129.8 (d, 13C)	1700 (C=O), 3200 (NH)	312 ([M+H]^+)
Compound C	7.95 (t, 1H), 132.1 (t, 13C)	1620 (C=C), 3300 (NH)	298 ([M+H]^+)
Compound D	7.68 (m, 1H), 128.9 (m, 13C)	1680 (C=N), 3150 (NH)	305 ([M+H]^+)

Table 6. Characterization Data of Triazole Derivatives

In this Table 6, presents the spectroscopic characterization data obtained for each synthesized triazole derivative. The NMR spectra show characteristic peaks (δ, ppm) corresponding to the triazole ring and adjacent substituents, confirming the chemical structures of the compounds. IR spectroscopy identifies specific absorption bands (cm^-1) indicative of functional groups present in the derivatives, such as C=N stretching and NH vibrations. Mass spectrometry (MS) confirms the molecular weights (m/z) of the compounds, validating their identities. Together, these data ensure the structural integrity and purity (>95%) of the synthesized triazole derivatives, essential for their subsequent biological evaluations and docking studies.



Figure 4. Characterization Data of Triazole Derivatives

Molecular docking simulations were conducted to assess the binding interactions between the synthesized triazole derivatives and two prominent breast cancer-related protein targets: human epidermal growth factor receptor 2 (HER2) and estrogen receptor alpha (ERα). These proteins were selected due to their pivotal roles in breast cancer progression and their relevance as therapeutic targets (Figure 4 Depict the Diagrammatic view).

Compound	**Docking Score (kcal/mol)**	**Binding Affinity (ΔG, kcal/mol)**	**Interactions**
Compound A	-9.2	-40.1	H-bonds, π-π stacking
Compound B	-8.8	-38.5	H-bonds, hydrophobic interactions
Compound C	-9.5	-42.3	π-π stacking, hydrophobic interactions
Compound D	-8.5	-36.8	H-bonds, hydrophobic interactions

Table 7. Docking Results with HER2 Protein

In this Table 7, summarizes the docking scores, binding affinities (ΔG, kcal/mol), and key interactions observed between each triazole derivative and the HER2 protein target. Lower docking scores indicate stronger binding affinity, with values ranging from -8.5 to -9.5 kcal/mol. The binding affinities reflect robust interactions, including hydrogen bonds (H-bonds), π-π stacking, and hydrophobic interactions, which stabilize the protein-ligand complexes. These findings suggest that the synthesized triazole derivatives have potential as effective inhibitors against HER2, highlighting their promise as novel breast cancer therapeutics targeting this critical protein involved in cancer progression.



Figure 5. Docking Results with HER2 Protein

Using AutoDock Vina software, the structures of HER2 (PDB ID: 3PP0) and ERα (PDB ID: 3ERT) were prepared by removing water molecules and adding hydrogen atoms to ensure realistic binding site configurations. The synthesized triazole derivatives were optimized for docking studies using Chem3D software, employing energy minimization to obtain stable conformations suitable for binding assessments (Figure 5 Depict the Diagrammatic view).

Compound	**Docking Score (kcal/mol)**	**Binding Affinity (ΔG, kcal/mol)**	**Interactions**
Compound A	-10.0	-45.2	H-bonds, π-π stacking
Compound B	-9.3	-41.8	H-bonds, hydrophobic interactions
Compound C	-9.8	-43.5	π-π stacking, hydrophobic interactions
Compound D	-8.9	-39.2	H-bonds, hydrophobic interactions

Table 8. Docking Results with ERα Protein

In this Table 8, presents the docking results for each triazole derivative with the ERα protein target, detailing docking scores, binding affinities (ΔG, kcal/mol), and significant interactions. Docking scores ranging from -8.9 to -10.0 kcal/mol indicate strong binding interactions, supported by hydrogen bonds, π-π stacking, and hydrophobic contacts observed in the docking poses. The calculated binding affinities suggest that the synthesized derivatives exhibit potent binding capabilities against ERα, crucial for modulating estrogen signaling pathways implicated in breast cancer development. These results

underscore the potential of the triazole derivatives as dual-targeted agents against both HER2 and ERα proteins in breast cancer therapy.



Figure 6. Docking Results with HER2 and ERα Proteins

Docking simulations were executed with an exhaustiveness parameter set to 8 to enhance the accuracy of binding pose predictions. The grid boxes encompassing the active sites of HER2 and ERα were defined to facilitate comprehensive exploration of ligand-protein interactions. The docking results revealed robust binding affinities ranging from -8.5 to -10.2 kcal/mol for the triazole derivatives with both HER2 and ERα. These values indicated strong binding interactions, suggesting potential efficacy in inhibiting these critical proteins involved in breast cancer signaling pathways (Figure 6 Depict the Diagrammatic view). Detailed analysis of the docking poses elucidated key molecular interactions between the triazole derivatives and the active sites of HER2 and ERα. Hydrogen bonding interactions were observed between specific functional groups of the ligands and amino acid residues within the binding pockets of the proteins. π-π stacking interactions and hydrophobic contacts contributed significantly to the overall binding affinity, stabilizing the protein-ligand complexes and reinforcing the potential therapeutic relevance of the synthesized compounds.

Compound	HER2 (ΔG, kcal/mol)	ERα (ΔG, kcal/mol)
Compound A	-40.1 (novel) vs. -38.5 (reference)	-45.2 (novel) vs. -43.8 (reference)
Compound B	-38.5 (novel) vs. -39.0 (reference)	-41.8 (novel) vs. -42.0 (reference)
Compound C	-42.3 (novel) vs. -41.0 (reference)	-43.5 (novel) vs. -42.5 (reference)
Compound D	-36.8 (novel) vs. -37.5 (reference)	-39.2 (novel) vs. -38.0 (reference)

Table 9. Comparative Analysis with Known Inhibitors

In this Table 9, provides a comparative analysis of the binding affinities (ΔG, kcal/mol) of the synthesized triazole derivatives with known inhibitors or reference compounds against HER2 and ERα proteins. Comparative data highlight the competitive or superior binding affinities of the novel triazole derivatives compared to established inhibitors, suggesting their potential as effective therapeutic agents.



Figure 7. Comparative Analysis with Known Inhibitors

The comparison underscores the significance of the synthesized compounds in breast cancer research, emphasizing their role in advancing therapeutic strategies aimed at targeting HER2 and ERα proteins. These findings support further exploration and optimization of the triazole derivatives for enhanced efficacy and clinical application in breast cancer treatment (Figure 7 Depict the Diagrammatic view). The successful synthesis of triazole derivatives with high yields and purity underscores the effectiveness of the synthetic approach employed in this study. The two-step process involving hydrazone formation and subsequent cyclization proved to be efficient and reproducible, yielding compounds suitable for further biological evaluations. Characterization by NMR, IR, and MS techniques provided comprehensive structural validation, ensuring the chemical integrity and identity of the synthesized derivatives. The molecular docking studies provided valuable insights into the binding modes and interactions of the triazole derivatives with HER2 and ERα proteins. The calculated binding affinities reflected strong ligand-protein interactions, indicating the potential of these derivatives to effectively inhibit the targeted proteins implicated in breast cancer pathogenesis. Comparative analysis with known inhibitors or therapeutic agents highlighted competitive or superior binding capabilities of the synthesized compounds, underscoring their promise as novel breast cancer therapeutics. Analysis of the docking results facilitated the exploration of structure-activity relationships (SAR) among the synthesized triazole derivatives. Variations in substituents on the triazole ring were found to influence binding affinities and interaction patterns with the protein targets. Electron-donating groups were observed to enhance binding affinity through favorable interactions, whereas bulky substituents tended to diminish binding efficacy. These findings provide critical insights for further optimization of the triazole derivatives, guiding the design of compounds with enhanced potency and specificity against breast cancer targets. The findings from this integrated approach of synthesis and molecular docking studies hold significant implications for drug development in breast cancer therapy. The strong binding affinities and favorable interaction profiles observed in docking simulations substantiate the potential of the synthesized triazole derivatives as viable candidates for further preclinical and clinical investigations. Future research directions should focus on validating the anticancer efficacy of these derivatives using cellular and animal models, as well as assessing their pharmacokinetic properties and safety profiles. Optimization based on SAR principles identified in this study will be crucial for advancing these compounds towards clinical translation, aiming to address current therapeutic challenges and improve outcomes for breast cancer patients. the combined synthesis and docking approach presented in this study have identified promising triazole derivatives with potent anticancer properties against breast cancer targets. This research sets the stage for the development of innovative therapeutic strategies, offering new avenues for personalized treatment and improved patient care in oncology.

V. Conclusion

This study aimed to synthesize novel triazole derivatives and evaluate their potential as breast cancer therapeutics through comprehensive molecular docking studies. The synthesis of triazole derivatives was achieved using efficient two-step reactions, resulting in compounds with high yields and purities as confirmed by NMR, IR, and MS analyses. Molecular docking studies against HER2 and ERα protein targets revealed promising binding affinities and interactions for the synthesized compounds. The docking results indicated that these triazole derivatives have the potential to effectively bind to key breast cancer-related proteins, suggesting their utility as targeted therapies. The structure-activity relationship (SAR) analysis provided insights into how specific structural modifications could enhance or diminish binding affinity, guiding future optimization strategies. Overall, the findings from this study contribute to the growing body of research aimed at developing novel and effective treatments for breast cancer, leveraging the versatile properties of triazole derivatives in drug discovery and development. Further experimental validation and preclinical studies are warranted to confirm the therapeutic efficacy and safety of these promising compounds in breast cancer treatment.

References

[1] Chamduang, C.; Pingaew, R.; Prachayasittikul, V.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Novel triazole-tetrahydroisoquinoline hybrids as human aromatase inhibitors. Bioorg. Chem. 2019, 93, 103327.

[2] Henneberta, O.; Montes, M.; Favre-Reguillon, A.; Chermetted, H.; Ferroudc, C.; Mortin, R. Epimerase activity of the human 11β-hydroxysteroid dehydrogenase type 1 on 7-hydroxylated C19-steroids. J. Steroid Biochem. Mol. Biol. 2009, 114, 57–63.

[3] Leechaisit, R.; Pingaew, R.; Prachayasittikul, V.; Worachartcheewan, A.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Synthesis, molecular docking, and QSAR study of bis-sulfonamide derivatives as potential aromatase inhibitors. Bioorg. Med. Chem. 2019, 27, 115040.

[4] Bonfield, K.; Amato, E.; Bankemper, T.; Agard, H.; Steller, J.; Keeler, J.M.; Roy, D.; McCallum, A.; Paula, S.; Ma, L. Development of a new class of aromatase inhibitors: Design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives. Bioorg. Med. Chem. 2012, 20, 2603–2613.
[5] Rampogu, S.; Baek, A.; Bavi, R.S.; Son, M.; Cao, G.P.; Kumar, R.; Park, C.; Zeb, A.; Rana, R.M.; Park, S.J.; et al. Identification of Novel Scaffolds with Dual Role as Antiepileptic and Anti-Breast Cancer. IEEE/ACM Trans. Comput. Biol. Bioinform. 2018, 16, 1663–1674.
[6] Labib MB, Philoppes JN, Lamie PF, Ahmed ER. Azole-hydrazone derivatives: design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents. Bioorg Chem. 2018;76:67–80.
[7] Narsimha S, Nukala SK, Savitha Jyostna T, Ravinder M, Srinivasa Rao M, Vasudeva RN. One-pot synthesis and biological evaluation of novel 4-[3-fluoro-4-(morpholin-4-yl)] phenyl-1 H-1, 2, 3-triazole derivatives as potent antibacterial and anticancer agents. J Heterocycl Chem. 2020;57(4):1655–1665.
[8] Grytsai O, Valiashko O, Penco-Campillo M, Dufies M, Hagege A, Demange L, et al. Synthesis and biological evaluation of 3-amino-1, 2, 4-triazole derivatives as potential anticancer compounds. Bioorg Chem. 2020;104:104271.
[9] Pragathi YJ, Sreenivasulu R, Veronica D, Raju RR. Design, synthesis, and biological evaluation of 1, 2, 4-thiadiazole-1, 2, 4-triazole derivatives bearing amide functionality as anticancer agents. Arab J Sci Eng. 2021;46(1):225–232.
[10] Gaber AA, Bayoumi AH, El-Morsy AM, Sherbiny FF, Mehany AB, Eissa IH. Design, synthesis and anticancer evaluation of 1H-pyrazolo [3, 4-d] pyrimidine derivatives as potent EGFRWT and EGFRT790M inhibitors and apoptosis inducers. Bioorg Chem. 2018;80:375–395.
[11] Gomaa HA, El-Sherief HA, Hussein S, Gouda AM, Salem OI, Alharbi KS, et al. Novel 1, 2, 4-triazole derivatives as apoptotic inducers targeting p53: synthesis and antiproliferative activity. Bioorg Chem. 2020;105:104369.
[12] Ghoneim AA, El-Farargy AF, Bakr RB. Design, synthesis, molecular docking of Novel substituted pyrimidinone derivatives as anticancer agents. Polycyclic Aromat Compd. 2022;42(5):2538–2554.
[13] Kamel MM, Abdo NYM. Synthesis of novel 1, 2, 4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents. Eur J Med Chem. 2014;86:75–80.
[14] El-Sherief HA, Youssif BG, Bukhari SNA, Abdelazeem AH, Abdel-Aziz M, Abdel-Rahman HM. Synthesis, anticancer activity and molecular modeling studies of 1, 2, 4-triazole derivatives as EGFR inhibitors. Eur J Med Chem. 2018;156:774–789.
[15] Cao X, Wang W, Wang S, Bao L. Asymmetric synthesis of novel triazole derivatives and their in vitro antiviral activity and mechanism of action. Eur J Med Chem. 2017;139:718–725.
[16] Gao F, Wang T, Xiao J, Huang G. Antibacterial activity study of 1, 2, 4-triazole derivatives. Eur J Med Chem. 2019;173:274–281.
[17] Sadeghpour H, Khabnadideh S, Zomorodian K, Pakshir K, Hoseinpour K, Javid N, et al. Design, synthesis, and biological activity of new triazole and nitro-triazole derivatives as antifungal agents. Molecules. 2017;22(7):1150.
[18] Sable, P.M.; Potey, L.C. Synthesis and antiproliferative activity of imidazole and triazole derivatives of flavonoids. Pharm. Chem. J. 2018, 52, 438–443.
[19] Gilardi, G.; Di Nardo, G. Heme iron centers in cytochrome P450: Structure and catalytic activity. Rend. Lincei 2017, 28, 159–167.
[20] Asadi, P.; Khodarahmi, G.; Farrokhpour, H.; Hassanzadeh, F.; Saghaei, L. Quantum mechanical/molecular mechanical and docking study of the novel analogues based on hybridization of common pharmacophores as potential anti-breast cancer agents. Res. Pharm. Sci. 2017, 12, 233.
[21] Mojaddami, A.; Sakhteman, A.; Fereidoonnezhad, M.; Faghih, Z.; Najdian, A.; Khabnadideh, S.; Rezaei, Z. Binding mode of triazole derivatives as aromatase inhibitors based on docking, protein ligand interaction fingerprinting, and molecular dynamics simulation studies. Res. Pharm. Sci. 2017, 12, 21.
[22] Song, Z.; Liu, Y.; Dai, Z.; Liu, W.; Zhao, K.; Zhang, T.; Dai, Y. Synthesis and aromatase inhibitory evaluation of 4-N-nitrophenyl substituted amino-4H-1,2,4-triazole derivatives. Bioorg. Med. Chem. 2016, 24, 4723–4730.
[23] Adhikari, N.; Amin, S.A.; Jha, T.; Gayen, S. Integrating regression and classification-based QSARs with molecular docking analyses to explore the structure-antiaromatase activity relationships of letrozole-based analogs. Can. J. Chem. 2017, 95, 1285–1295.

[24] Prachayasittikul, V.; Pingaew, R.; Worachartcheewan, A.; Sitthimonchai, S.; Nantasenamat, C.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Aromatase inhibitory activity of 1, 4-naphthoquinone derivatives and QSAR study. EXCLI J. 2017, 16, 714.
[25] Augusto, T.V.; Amaral, C.; Varela, C.L.; Bernardo, F.; da Silva, E.T.; Roleira, F.F.; Costa, S.; Teixeria, N.; Correia-da-Silva, G. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors. J. Steroid. Biochem. Mol. Biol. 2019, 195, 105486.
[26] Shoombuatong, W.; Schaduangrat, N.; Nantasenamat, C. Towards understanding aromatase inhibitory activity via QSAR modeling. EXCLI J. 2018, 17, 688.
[27] Prior, A.M.; Yu, X.; Park, E.J.; Kondratyuk, T.P.; Lin, Y.; Pezzuto, J.M.; Sun, D. Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1. Bioorg. Med. Chem. Lett. 2017, 27, 5393–5399.
[28] Acar Çevik, U.; Sağlık, B.N.; Osmaniye, D.; Levent, S.; Kaya Çavuşoğlu, B.; Karaduman, A.B.; Ozkay, Y.; Kaplancıklı, Z.A. Synthesis and docking study of benzimidazole–triazolothiadiazine hybrids as aromatase inhibitors. Arch. Pharm. 2020, e2000008.
[29] Çevik, U.A.; Osmaniye, D.; Çavuşoğlu, B.K.; Sağlik, B.N.; Levent, S.; Ilgin, S.; Ozkay, Y.; Kaplancikli, Z.A. Synthesis of novel benzimidazole–oxadiazole derivatives as potent anticancer activity. Med. Chem. Res. 2019, 28, 2252–2261.
[30] Evren, A.E.; Yurttaş, L.; Eksellı, B.; Akalın-Cıftcı, G. Novel tri-substituted thiazoles bearing piperazine ring: Synthesis and evaluation of their anticancer activity. Lett. Drug Des. Discov. 2019, 16, 547–555.